Dupixent
Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results
Kymera Therapeutics; KT-621; Dupixent-in-a-pill; oral STAT6 degrader; atopic dermatitis; eczema; BroADen Phase 1b trial; Dupixent rival; Type 2 inflammation; early clinical data
Dupixent Gains EU Approval as First Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade
Dupixent; chronic spontaneous urticaria (CSU); EU approval; Sanofi; Regeneron; monoclonal antibody; IL-4; IL-13; CUPID phase 3 trials; type 2 inflammation
Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations
Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction
Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical
Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership
FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid
Dupixent; Dupilumab; Sanofi; Regeneron; bullous pemphigoid; FDA approval; type 2 inflammation; autoimmune disease; priority review; orphan drug
Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge
Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration
Dupixent notches seventh disease approval with urticaria nod
Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh
Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement
Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025
Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines